PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Klimek, L.* ; Hoffmann, H.J.* ; Kalpaklioglu, A.F.* ; Demoly, P.* ; Agache, I.* ; Popov, T.A.* ; Muraro, A.* ; Schmid-Grendelmeier, P.* ; Bonini, S.* ; Bonertz, A.* ; Mahler, V.* ; Vieths, S.* ; Pfaar, O.* ; Zuberbier, T.* ; Jutel, M.* ; Schmidt-Weber, C.B. ; Hellings, P.W.* ; Dreborg, S.* ; Bonini, M.* ; Brough, H.A.* ; Bouquet, A.* ; Hoffmann-Sommergruber, K.* ; Palomares, O.* ; Ollert, M.* ; Shamji, M.H.* ; Cardona, V.*

In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan-An EAACI position paper.

Allergy 75, 2161-2169 (2020)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Diagnostic allergens are defined as medicinal products in the EU. Marketing authorization by national authorities is necessary; however, diagnostic allergens are not homogeneously regulated in different EU member states. Allergen manufacturers argue with increasing costs forcing them to continuously reduce the diagnostic allergen portfolios offered to allergists. In contrast, EAACI and national European Allergy Societies see the need for the availability of a wide range of high-quality diagnostic allergens for in vivo diagnosis of IgE-mediated allergies not only covering predominant but also less frequent allergen sources. In a recent EAACI task force survey, the current practice of allergy diagnosis was shown to rely on skin tests as first option in almost 2/3 of all types of allergic diseases and in 90% regarding respiratory allergies. With the need to ensure the availability of high-quality diagnostic allergens in the EU, an action plan has been set up by EAACI to analyse the current regulatory demands in EU member states and to define possible solutions stated in this document: (a) simplification of authorization for diagnostic allergens; (b) specific regulation of special types of diagnostic allergens; (c) new models beyond the current model of homologous groups; (d) simplification of pharmacovigilance reporting; (e) reduction of regulation fees for diagnostic allergens; (f) reimbursement for diagnostic allergens. Joining forces of allergists, manufacturers and authorities are of high importance to ensure remaining relevant allergens in the EU markets to facilitate a sustainable and comprehensive service for the diagnosis and treatment of allergic diseases.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
8.706
0.000
11
12
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Allergen Provocation Test ; European Pharmacopoeia ; Marketing Authorization ; Regulatory Framework ; Skin Prick Test ; Skin Test Allergens; Immunotherapy; Legislation; Availability; Provocation; Guidelines; Diseases; Children; Impact
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0105-4538
e-ISSN 1398-9995
Zeitschrift Allergy
Quellenangaben Band: 75, Heft: 9, Seiten: 2161-2169 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Allergy Research (IAF)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Allergy
PSP-Element(e) G-505400-001
DOI 10.1111/all.14329
WOS ID WOS:000569864500002
Scopus ID 85089096167
PubMed ID 32306414
Erfassungsdatum 2020-11-12
[➜Korrektur melden]